Major General James G. Blunt

PF-03550096 is a drug that acts as a potent agonist for the CB₂ cannabinoid receptor, with good selectivity over CB₁ having K_i values of 7nM at CB₂ and 1500nM at CB₁. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,^[1] but has only progressed to animal studies.^[2]

References

^ WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc.
^ Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.

[1] WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc.

[2] Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.

[1]

[2]

See also

References